Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by STE15165on Aug 20, 2014 8:58am
422 Views
Post# 22859157

CNBG

CNBG
Was concerned and asked Fred about Wuhan development. I really admire him. He's a very upfront guy. Here's what he said. Hi Steve, I have not heard anything at my end that would cause me to worry regarding CNBG. From what I know, we continue to work very closely with our partners in China (CNBG) and also in Taiwan (Hematech). I believe that the progress recently realized by Prometic both from the manufacturing and regulatory pathways with our PPPS process and plasma purification facility combined with the FDA favorable stance for our PPPS process will also prove to be useful for their own regulatory filings as well since there has been a constant exchange of information between the 2 organizations. I do not have an exact timeline just yet as to when they will start filing their INDs with their regulatory body, so I cannot provide more info on this at the moment. As important as CNBG is for our base case and product sales (resin sales and royalties on therapeutic sales in China), I also believe that we will see even more significant growth from our own plasma derived therapeutics once they are approved and start to be commercialized. Again, from what I know, it is still the plan to end up with up to 3 plasma purification facility in China over the coming years. Rest assured that we will provide any update as soon as they become available. Tks Best regards, Fred
Bullboard Posts